Comparing Clopidogrel and Cilostazol for preventing cardiovascular issues in diabetics
Comparing Clopidogrel and Cilostazol in Type 2 Diabetes Patients With Carotid Atherosclerosis
This study is testing whether the medications Clopidogrel and Cilostazol can help prevent heart problems in adults with type 2 diabetes who have early signs of artery hardening.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 19 Years and up |
| Sex | All |
| Sponsor | Seoul National University Bundang Hospital Academic / other |
| Locations | 1 site (Seongnam-si, Gyeonggi-do) |
| Trial ID | NCT06402747 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of Clopidogrel and Cilostazol in preventing cardiovascular diseases among adults with type 2 diabetes who show early signs of atherosclerosis. Participants will undergo carotid ultrasound to measure carotid intima-media thickness, which helps assess their cardiovascular risk. The study aims to determine if these medications can inhibit the progression of carotid atherosclerosis in this high-risk population. By evaluating these treatments, the trial seeks to provide insights into their potential role in primary prevention strategies for cardiovascular complications in diabetics.
Who should consider this trial
Good fit: Ideal candidates are adults aged 19 and older with type 2 diabetes and a carotid intima-media thickness of 1.0mm or more.
Not a fit: Patients currently using antithrombotic or anticoagulant medications other than aspirin may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prevention strategies for cardiovascular diseases in patients with type 2 diabetes.
How similar studies have performed: While the use of Clopidogrel and Cilostazol has been established for symptom control, their role in primary prevention for this specific population is still being explored, making this approach relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults with diabetes aged 19 and older * Individuals with a carotid ultrasound cIMT (carotid intima-media thickness) of 1.0mm or more * Those who have not changed their combination therapy medications (including oral hypoglycemics, antihypertensives, and lipid-lowering drugs) in the last three months * Individuals with an HbA1c level of 10% or less * Those who have voluntarily signed the written consent form and agreed to participate in the study Exclusion Criteria: * Individuals currently using antithrombotic or anticoagulant medications other than aspirin * Individuals with bleeding or conditions that may increase the risk of bleeding, such as: * Hemophilia, capillary fragility, intracranial hemorrhage, upper gastrointestinal bleeding, urinary bleeding, hemoptysis, vitreous hemorrhage, etc * Active peptic ulcer, hemorrhagic stroke within the last 6 months, surgical operations within the last 3 months, proliferative diabetic retinopathy, uncontrolled hypertension * Patients who have had cerebrovascular or cardiovascular complications within the past 6 months (including stroke, transient ischemic attacks, myocardial infarction, unstable angina, coronary artery bypass graft, or percutaneous coronary intervention) * Patients with severe renal or hepatic diseases * Patients with congestive heart failure * Individuals with a history of hypersensitivity to the drug or its components * Pregnant women or women who may be pregnant * Women who are breastfeeding or plan to breastfeed during the study
Where this trial is running
Seongnam-si, Gyeonggi-do
- Seoul National University Bundang Hospital — Seongnam-si, Gyeonggi-do, South Korea (Recruiting)
Study contacts
- Principal investigator: Soo Lim, MD. Ph.D. — Seoul National University Bundang Hospital
- Study coordinator: Soo Lim, MD. Ph.D.
- Email: limsoo@snu.ac.kr
- Phone: +82317877035
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.